Immunotherapy (Transfusion Medicine)

Genetically Modified Dendritic Cells Exhibit Potent Adjuvant Effect

Published in Cancer Weekly, September 29th, 1997

Retroviral transduction of human dendritic cells does not alter their specialized accessory properties and can be used as a potent endogenous adjuvant in immunization protocols.

Immunization requires the introduction of an antigen coupled with an adjuvant which stimulates a required inflammatory reaction to boost the host's immune response. Dendritic cells have been termed "nature's adjuvant" as they are the most potent naturally-occurring, T-cell stimulating, accessory cell. They are attractive adjuvant candidates for vaccine-based immunotherapy because of their potential to function as natural adjuvants for poorly immunogenic proteins derived from microbes or...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-09-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry